{"id":19609,"date":"2023-04-14T12:50:00","date_gmt":"2023-04-14T04:50:00","guid":{"rendered":"https:\/\/flcube.com\/?p=19609"},"modified":"2024-12-24T12:55:38","modified_gmt":"2024-12-24T04:55:38","slug":"huidagene-therapeutics-enhances-crispr-cas12f-system-with-higher-editing-efficiency","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=19609","title":{"rendered":"HuidaGene Therapeutics Enhances CRISPR-Cas12f System with Higher Editing Efficiency"},"content":{"rendered":"\n<p>HuidaGene (Shanghai) Therapeutics Co., Ltd, a China-based biotechnology company, has made significant strides in the field of CRISPR-Cas genome editing technology. Through protein and sgRNA engineering, HuidaGene has enhanced the OsCas12f1 (enOsCas12f1) and enRhCas12f1 variants of the CRISPR-Cas12f system. These variants exhibit much higher editing efficiency and possess broader PAMs (5\u2019-TTN and 5\u2019-CCD, where D is not C) compared to the previously engineered variant Un1Cas12f1 (Un1Cas12f1_ge4.1).<\/p>\n\n\n\n<p><strong>Enhanced CRISPR-Cas12f Variants<\/strong><br>The enhancements made by HuidaGene to the CRISPR-Cas12f system are notable for their potential to revolutionize genome editing. The company&#8217;s work has led to the development of inducible-activated DD enOsCas12f1, an epigenetic editor known as miniCRISPRoff, and a gene expression activator (denOsCas12f1-VPR). These tools expand the capabilities of the CRISPR-Cas12f system, offering more precise and versatile editing options for researchers and scientists.<\/p>\n\n\n\n<p><strong>Details and Applications<\/strong><br>More details on HuidaGene&#8217;s advancements in the CRISPR-Cas12f system can be found on their official channels. The company&#8217;s work is expected to have a significant impact on the biotechnology and medical fields, as these enhanced variants offer broader applications in gene editing and could lead to breakthroughs in treating genetic diseases and improving crop genetics.<a href=\"https:\/\/flcube.com\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>HuidaGene (Shanghai) Therapeutics Co., Ltd, a China-based biotechnology company, has made significant strides in the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,6],"tags":[111,66,1619],"class_list":["post-19609","post","type-post","status-publish","format-standard","hentry","category-company","category-rd","tag-crispr","tag-gene-therapy","tag-huidagene-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>HuidaGene Therapeutics Enhances CRISPR-Cas12f System with Higher Editing Efficiency - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"HuidaGene (Shanghai) Therapeutics Co., Ltd, a China-based biotechnology company, has made significant strides in the field of CRISPR-Cas genome editing technology. Through protein and sgRNA engineering, HuidaGene has enhanced the OsCas12f1 (enOsCas12f1) and enRhCas12f1 variants of the CRISPR-Cas12f system. These variants exhibit much higher editing efficiency and possess broader PAMs (5\u2019-TTN and 5\u2019-CCD, where D is not C) compared to the previously engineered variant Un1Cas12f1 (Un1Cas12f1_ge4.1).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=19609\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HuidaGene Therapeutics Enhances CRISPR-Cas12f System with Higher Editing Efficiency\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=19609\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-14T04:50:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-24T04:55:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19609#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19609\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"HuidaGene Therapeutics Enhances CRISPR-Cas12f System with Higher Editing Efficiency\",\"datePublished\":\"2023-04-14T04:50:00+00:00\",\"dateModified\":\"2024-12-24T04:55:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19609\"},\"wordCount\":222,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"CRISPR\",\"Gene therapy\",\"HuidaGene Therapeutics\"],\"articleSection\":[\"Company\",\"R&amp;D\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19609#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19609\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=19609\",\"name\":\"HuidaGene Therapeutics Enhances CRISPR-Cas12f System with Higher Editing Efficiency - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-04-14T04:50:00+00:00\",\"dateModified\":\"2024-12-24T04:55:38+00:00\",\"description\":\"HuidaGene (Shanghai) Therapeutics Co., Ltd, a China-based biotechnology company, has made significant strides in the field of CRISPR-Cas genome editing technology. Through protein and sgRNA engineering, HuidaGene has enhanced the OsCas12f1 (enOsCas12f1) and enRhCas12f1 variants of the CRISPR-Cas12f system. These variants exhibit much higher editing efficiency and possess broader PAMs (5\u2019-TTN and 5\u2019-CCD, where D is not C) compared to the previously engineered variant Un1Cas12f1 (Un1Cas12f1_ge4.1).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19609#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19609\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19609#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HuidaGene Therapeutics Enhances CRISPR-Cas12f System with Higher Editing Efficiency\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"HuidaGene Therapeutics Enhances CRISPR-Cas12f System with Higher Editing Efficiency - Insight, China&#039;s Pharmaceutical Industry","description":"HuidaGene (Shanghai) Therapeutics Co., Ltd, a China-based biotechnology company, has made significant strides in the field of CRISPR-Cas genome editing technology. Through protein and sgRNA engineering, HuidaGene has enhanced the OsCas12f1 (enOsCas12f1) and enRhCas12f1 variants of the CRISPR-Cas12f system. These variants exhibit much higher editing efficiency and possess broader PAMs (5\u2019-TTN and 5\u2019-CCD, where D is not C) compared to the previously engineered variant Un1Cas12f1 (Un1Cas12f1_ge4.1).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=19609","og_locale":"en_US","og_type":"article","og_title":"HuidaGene Therapeutics Enhances CRISPR-Cas12f System with Higher Editing Efficiency","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=19609","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-04-14T04:50:00+00:00","article_modified_time":"2024-12-24T04:55:38+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=19609#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=19609"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"HuidaGene Therapeutics Enhances CRISPR-Cas12f System with Higher Editing Efficiency","datePublished":"2023-04-14T04:50:00+00:00","dateModified":"2024-12-24T04:55:38+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=19609"},"wordCount":222,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["CRISPR","Gene therapy","HuidaGene Therapeutics"],"articleSection":["Company","R&amp;D"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=19609#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=19609","url":"https:\/\/flcube.com\/?p=19609","name":"HuidaGene Therapeutics Enhances CRISPR-Cas12f System with Higher Editing Efficiency - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-04-14T04:50:00+00:00","dateModified":"2024-12-24T04:55:38+00:00","description":"HuidaGene (Shanghai) Therapeutics Co., Ltd, a China-based biotechnology company, has made significant strides in the field of CRISPR-Cas genome editing technology. Through protein and sgRNA engineering, HuidaGene has enhanced the OsCas12f1 (enOsCas12f1) and enRhCas12f1 variants of the CRISPR-Cas12f system. These variants exhibit much higher editing efficiency and possess broader PAMs (5\u2019-TTN and 5\u2019-CCD, where D is not C) compared to the previously engineered variant Un1Cas12f1 (Un1Cas12f1_ge4.1).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=19609#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=19609"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=19609#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"HuidaGene Therapeutics Enhances CRISPR-Cas12f System with Higher Editing Efficiency"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19609","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19609"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19609\/revisions"}],"predecessor-version":[{"id":19610,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19609\/revisions\/19610"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19609"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19609"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19609"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}